tetano
Editor, Senior Moderator
Hum Cell
. 2020 Oct 9.
doi: 10.1007/s13577-020-00444-5. Online ahead of print.
Umbilical cord: an allogenic tissue for potential treatment of COVID-19
Hugo C Rodriguez[SUP] 1 2 3 4 [/SUP], Manu Gupta[SUP] 1 [/SUP], Emilio Cavazos-Escobar[SUP] 2 5 [/SUP], Saadiq F El-Amin 3rd[SUP] 6 7 [/SUP], Ashim Gupta[SUP] 8 9 10 11 [/SUP]
Affiliations
Abstract
The COVID-19 pandemic has placed an unprecedented burden on health care systems and economies around the globe. Clinical evidences demonstrate that SARS-CoV-2 infection produces detrimental levels of pro-inflammatory cytokines and chemokines that can lead to acute respiratory distress syndrome (ARDS) and significant systemic organ damage. Currently, there is no definitive therapy for COVID-19 or associated complications, and with the hope of a safe and effective vaccine in the distant future, the search for an answer is paramount. Mesenchymal stem cells (MSCs) provide a viable option due to their immunomodulatory effects and tissue repair and regeneration abilities. Studies have demonstrated that compassionate use of MSCs can reduce symptoms associated with SARS-CoV-2 infection, eliminate fluid buildup, and act as a regenerative technique for alveolar damage; all in a safe and effective way. With multiple autologous sources available for MSCs, each with their own respective limitations, allogenic umbilical cord (UC) and/or UC-derived Wharton's jelly (WJ) seem to be best positioned source to harvest MSCs to treat COVID-19 and associated symptoms. As an allogenic source, UC is readily available, easily obtainable, and is rich in immunomodulatory and regenerative factors. In this manuscript, we reviewed the current evidences and explored the potential therapeutic use of allogenic UC and/or WJ-derived MSCs for the treatment of COVID-19. Although, preliminary preclinical and clinical studies indicate that their use is safe and potentially effective, more multi-center, randomized, controlled trials are needed to adequately assess the safety and efficacy of UC and/or WJ-derived MSCs for the treatment of COVID-19.
Keywords: COVID-19; Coronavirus; Mesenchymal stem cells; Umbilical cord; Wharton’s jelly.
. 2020 Oct 9.
doi: 10.1007/s13577-020-00444-5. Online ahead of print.
Umbilical cord: an allogenic tissue for potential treatment of COVID-19
Hugo C Rodriguez[SUP] 1 2 3 4 [/SUP], Manu Gupta[SUP] 1 [/SUP], Emilio Cavazos-Escobar[SUP] 2 5 [/SUP], Saadiq F El-Amin 3rd[SUP] 6 7 [/SUP], Ashim Gupta[SUP] 8 9 10 11 [/SUP]
Affiliations
- PMID: 33033884
- DOI: 10.1007/s13577-020-00444-5
Abstract
The COVID-19 pandemic has placed an unprecedented burden on health care systems and economies around the globe. Clinical evidences demonstrate that SARS-CoV-2 infection produces detrimental levels of pro-inflammatory cytokines and chemokines that can lead to acute respiratory distress syndrome (ARDS) and significant systemic organ damage. Currently, there is no definitive therapy for COVID-19 or associated complications, and with the hope of a safe and effective vaccine in the distant future, the search for an answer is paramount. Mesenchymal stem cells (MSCs) provide a viable option due to their immunomodulatory effects and tissue repair and regeneration abilities. Studies have demonstrated that compassionate use of MSCs can reduce symptoms associated with SARS-CoV-2 infection, eliminate fluid buildup, and act as a regenerative technique for alveolar damage; all in a safe and effective way. With multiple autologous sources available for MSCs, each with their own respective limitations, allogenic umbilical cord (UC) and/or UC-derived Wharton's jelly (WJ) seem to be best positioned source to harvest MSCs to treat COVID-19 and associated symptoms. As an allogenic source, UC is readily available, easily obtainable, and is rich in immunomodulatory and regenerative factors. In this manuscript, we reviewed the current evidences and explored the potential therapeutic use of allogenic UC and/or WJ-derived MSCs for the treatment of COVID-19. Although, preliminary preclinical and clinical studies indicate that their use is safe and potentially effective, more multi-center, randomized, controlled trials are needed to adequately assess the safety and efficacy of UC and/or WJ-derived MSCs for the treatment of COVID-19.
Keywords: COVID-19; Coronavirus; Mesenchymal stem cells; Umbilical cord; Wharton’s jelly.